TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03593096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study: NCT00767962

Intervention type: OTHER
Group type: OTHER
Intervention: talc pleurodesis under medical thoracoscopy
Description: talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax

Intervention type: OTHER
Group type: OTHER
Intervention: pleurodesis under video-assisted thoracoscopy surgery
Description: pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
Study: NCT04337268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-Like Peptide 1
Description: Intravenous infusion (1.5 pmol/kg/min) for 60 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9%
Description: Intravenous infusion for 60 min.
Study: NCT02506673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Conductance Monitor
Study: NCT03965988

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02506673

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Skin Conductance Monitor
Study: NCT01194037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant variant of interferon-alpha 2b
Description: SC, Weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant variant of interferon-alpha 2b
Description: SC, Weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: SC Weekly
Study: NCT03817229

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education microlearning sessions
Description: mHealth education microlearning sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education microlearning sessions
Description: mHealth education microlearning sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Automated digital reminders
Description: reminders from electronic monitors based on texts or lights/chimes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated digital reminders
Description: reminders from electronic monitors based on texts or lights/chimes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving mHealth module
Description: mhealht problem solving module with 2 telehealth sessions with a therapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Adherence Feedback Report
Description: Individual Adherence Feedback reports sent to parents weekly
Study: NCT03416751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplant
Description: Fecal transplant from a donor in the OpenBiome Registry

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo enemas
Study: NCT03711318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Description: 3 week treatment with buprenorphine/naloxone
Study: NCT01373242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid peanut extract (Peanut SLIT)
Description: Liquid peanut extract will be administered under the tongue
Study: NCT01781364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Fitness Training, Posit Science SF
Description: Computer aided cognitive training based on principles of neuroplasticity
Study: NCT05840640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard medical therapy involves primary treatment with normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: standard medical therapy plus G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF and NAC
Description: Standard Medical Therapy plus G-CSF with intravenous NAC (day 1: NAC at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution followed by oral NAC from days 6 to 28)
Study: NCT04974983

Intervention type: OTHER
Intervention: Observation of neurological deficits
Description: Observation of neurological deficits
Study: NCT04850482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyJourney
Description: MyJourney is an online self-help interactive program based on Contextual Cognitive Behavioural Therapy.
Study: NCT01221337

Intervention type: OTHER
Group type: OTHER
Intervention: heparin free haemodialysis
Description: Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH).

Intervention type: OTHER
Group type: OTHER
Intervention: heparin free haemodialysis
Description: Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH).
Study: NCT03146351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family based early intervention program (NDT-Bobath based)
Description: Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family based early intervention program (NDT-Bobath based)
Description: Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
Study: NCT04593797

Intervention type: DIAGNOSTIC_TEST
Intervention: carotid blood flow measurement with ultrasound
Description: carotid blood flow measurement with ultrasound vs transpulmonary thermodilution calibrated continuous cardiac output measurements
Study: NCT03545984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulation-based learning
Description: Simulation-based teaching involves using done on a mannequin to simulate actual conditions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: interactive problem based learning
Description: Standard teaching (problem based learning discussion) during cardiac/vascular rotation
Study: NCT02555631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle
Description: In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
Study: NCT03418324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.
Study: NCT04546997

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography Angiography
Description: Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography Angiography
Description: Patients underwent non-invasive, fast, diagnostic imaging technique (optical coherence tomography angiography)
Study: NCT02840994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV301

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study: NCT00290706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
Study: NCT02633189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: given orally 150 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: given orally 150 mg daily
Study: NCT01073696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: granisetron IV
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron patch
Description: patch
Study: NCT00050349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO906 epothilone B
Study: NCT04169334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged planned program for the stay at the obstetric department
Description: A five day planned and designed program delivered to the family while at the obstetric department.
Study: NCT01052168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skills training
Description: participants will train using different performance goals (based on different metrics)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skills training
Description: participants will train using different performance goals (based on different metrics)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skills training
Description: participants will train using different performance goals (based on different metrics)
Study: NCT03666260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum Block
Description: Quadratus Lumborum Block with echography
Study: NCT05470777

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD22/CD19 CAR T and auto-HSCT sandwich strategy
Description: The patients received sequential infusion of CD22 and CD19 CAR-T cells (co-stimulatory molecule was 4-1BB and infusion dose was 5\*10\^6/kg respectively) after standard induction and consolidation chemotherapy. Autologous stem cells mobilization and collection were performed 6-8 weeks after CAR-T infusion. Standard BuCy as conditioning regimen for Auto-HSCT was used 4 weeks after successful stem cell collection. CD22 and CD19 CAR-T cells were re-infused 2 days after Auto-HSCT. Patients were followed up and minimal residual diseases (MRD) was monitored by flow cytometry and second-generation gene sequencing of IgH rearrangement.
Study: NCT00955578

Intervention type: PROCEDURE
Intervention: Punch Biopsy
Description: 5-6 punch biopsies of affected areas
Study: NCT03666260

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral block
Description: femoral block with echography
Study: NCT02255812

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Single intragastric instillation of 200 mL tap water via nasogastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube
Study: NCT03223324

Intervention type: DEVICE
Intervention: abdominal fetal/maternal monitor
Description: A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
Study: NCT03603600

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enVista MX60E
Description: enVista MX60E monofocal IOL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: enVista MX60EF
Description: enVista MX60EF (trifocal) multifocal IOL (MIOL)
Study: NCT04258111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI310 (anti-CTLA-4 antibody)
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab(anti-PD-1 antibody)
Description: Specified dose on specified days
Study: NCT03766672

Intervention type: DIAGNOSTIC_TEST
Intervention: Intervention Arm
Description: The intervention consists to the characterization of molecular mechanisms using to Next Generation Sequencing (NGS) technique.
Study: NCT02633189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg intravenously every 21 days.
Study: NCT01985399

Intervention type: BEHAVIORAL
Intervention: Neuropsychological testing
Description: Neuropsychological testing
Study: NCT01785433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 4.5 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 4.5 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 4.5 mcg
Study: NCT04066738

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac MRI with gadolinium contrast
Description: Imaging of left ventricular scar and coronary sinus venous system

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 3D reconstruction and location of coronary sinus venous system relative to myocardial scar
Description: Three dimensional mapping of coronary sinus venous system with Abbott Precision mapping system and Biotronik Vision wire Merge with MRI images of CS and myocardial scar

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Acute haemodynamic measurements during CRT implant
Description: Advancement of pressure wire to LV cavity via femoral/radial arterial access. Real time measurement of LV-dP/dTmax during conventional CRT and MPP after consecutive placement of LV lead in two different CS branches (peri-infarct region and remote myocardium)
Study: NCT02204618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implantation

Intervention type: OTHER
Group type: OTHER
Intervention: 6 months initial abstention
Description: Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
Study: NCT00605033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484
Description: Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subutex, Buprenorphine Hydrochloride, SCH 28444
Description: Subutex sublingual tablet 4-24 mg, daily for 28 days
Study: NCT01844544

Intervention type: OTHER
Intervention: inspection of medical records
Study: NCT03768206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy
Description: Participants will receive standard outpatient physical therapy that is typical following knee replacement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Participants will receive standard outpatient physical therapy that is typical following knee replacement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapist discuss aerobic physical activity
Description: Physical therapists will provide recommendations to increase aerobic physical activity and set goals during standard physical therapy sessions after knee replacement.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity session
Description: Participants will receive a one hour coaching session on aerobic physical activity and goal setting after knee replacement.
Study: NCT03398811

Intervention type: DRUG
Intervention: Depot medroxy-progesterone acetate
Description: Injection every 3 months

Intervention type: DRUG
Intervention: Etonogestrel
Description: 68 mg implant

Intervention type: DRUG
Intervention: Desogestrel 75 µg
Description: one pill every day for 28 days without pill-free interval.
Study: NCT01233154

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic
Study: NCT04218669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y Hepaticojejunostomy
Description: The common hepatic duct was cut and the duodenal side is closed by suture. The small intestine was cut off 15 cm below the ligament of Treitz. The distal end was lifted, and a 1-2 cm incision was made at the jejunal wall 4-5 cm from the jejunal stump. The anastomosis is used a 5-0 PSD Ⅱ suture, with double needles, inside-out in the jejunum and outside-in in the hepatic duct. One side of needles was used to continuely penetrate and suture the whole layer of the posterior-lateral wall of the jejunum, the posterior-lateral wall of the biliary duct, and the other side of needles was used to continuely stuere the anterior part of the anastomosis. Mucosa-to-mucosa contact should be ensured with every stitch.The anastomotic stomas were then checked for leakage. Enteric-enteric anastomosis was performed 60 cm below the site of the hepatojejunal anastomosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-tube drainage
Description: The T-tube was placed for biliary drainage and the common bile duct was intermittently sutured with 4-0 vicryl sutures.
Study: NCT00908336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel and Erlotinib
Description: Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: 150 mg/day po daily
Study: NCT04251143

Intervention type: PROCEDURE
Intervention: corneal cross-linking
Description: UV-A Irradiation and riboflavin
Study: NCT01785433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 4.5 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium HFA BAI 9.0 mcg
Study: NCT04251143

Intervention type: DIAGNOSTIC_TEST
Intervention: corneal topography and tomography
Description: Detailed Information about corneal tomography is used for diagnosis
Study: NCT04296032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality game traning
Description: The controllers were attached to upper extremity to control the game. The game could train the shoulder, elbow, and wrist control.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: The program included bilateral hand, grasp/release, and pinch activities.
Study: NCT02588196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Study: NCT02147587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 5 mg twice daily of tofacitinib with background methotrexate for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets twice daily with background methotrexate for 12 weeks
Study: NCT02184741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-0998
Description: Subjects received GB-0998 at 400 mg/kg body weight once daily for 5 days until 6 weeks and 6 days of gestation after confirmation of the gestational sac by ultrasonography.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received the same dose of saline as GB-0998 for 5 days after confirmation of the gestational sac by ultrasonography, up to 6 weeks and 6 days of gestation.
Study: NCT02401841

Intervention type: DRUG
Intervention: Two different types of drug for resolution of neuro-muscular blockade

Intervention type: DRUG
Intervention: Two different types of drug for resolution of neuro-muscular blockade
Study: NCT04296032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: The program included bilateral hand, grasp/release, and pinch activities.
Study: NCT03657238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD01
Description: single S.C. dose of RD01 for subjects in test group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single S.C. dose of placebo for subjects in placebo group